Inhibrx, Inc.

NASDAQ:INBX

13.56 (USD) • At close February 5, 2025
Bedrijfsnaam Inhibrx, Inc.
Symbool INBX
Munteenheid USD
Prijs 13.56
Beurswaarde 196,293,258
Dividendpercentage 0%
52-weken bereik 10.8 - 18.95
Industrie Biotechnology
Sector Healthcare
CEO Mr. Mark Paul Lappe
Website https://inhibrx.com

An error occurred while fetching data.

Over Inhibrx, Inc.

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional

Vergelijkbare Aandelen

Cullinan Oncology, Inc. logo

Cullinan Oncology, Inc.

CGEM

10.3 USD

Intercept Pharmaceuticals, Inc. logo

Intercept Pharmaceuticals, Inc.

ICPT

19 USD

Nano-X Imaging Ltd. logo

Nano-X Imaging Ltd.

NNOX

7.28 USD

ANI Pharmaceuticals, Inc. logo

ANI Pharmaceuticals, Inc.

ANIP

59.81 USD

Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc.

CRBU

1.46 USD

Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSC

0.796 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)